BPG is committed to discovery and dissemination of knowledge
Review
Copyright: ©Author(s) 2026.
World J Immunol. Nov 20, 2026; 16(3): 125225
Published online Nov 20, 2026. doi: 10.5411/wji.125225
Table 1 Modulation of metainflammation in the treatment of metabolic liver diseases
Drugs
Clinical trials
Phases
Mechanisms/aims
Ref.
HEC88473, a dual agonist of GLP-1 and FGF21NCT059438861Improvement in glycemic control and lipid metabolism.
Reduction in hepatic fat fraction
[98]
PegozaferminNCT04048135; NCT04929483; NCT064193741/2; 2; 3Improvement in glycemic control, serum lipids, and liver injury and fibrosis[99,100]
Lanifibranor, a PPAR pan-agonistNCT034590792Improvement in glucose and lipid metabolism. Inhibition of hepatic and peripheral insulin resistance[101]
Chiglitazar, a PPAR pan-agonistNCT051939162Improvement of liver injury. Reduction in liver fat content[102]
Probiotics: LL001, LH001, and PPKID7NCT045554341/2Improvement in liver injury. Body weight loss. Reduction in total cholesterol[103]
Three consecutive FMTsNCT044650324Change of gut microbiota alpha diversity[104]
Fonte essenzialeNCT07211113Not applicableReduction of intestinal permeability. Inhibition of systemic inflammation and oxidative stress[105]
Dietary supplementation with dihydromyricetin, vitamin C, E, and cholineNCT05052515Not applicableAntioxidant activity and glycemic control. Improvement in sugar and lipid metabolism[106,107]


Write to the Help Desk